CAR-T Cell Research
Cancer Immuno-Therapy
Our Cell Therapy Division develops advanced CAR-T cell therapies targeting soft (humorless) cancers, including non-Hodgkin's lymphoma and leukemia. We engineer patients' own T-cells to recognize and destroy cancer cells with unprecedented precision.
Autoimmune Trials
We are actively pursuing early-phase clinical trials applying CAR-T technology to autoimmune conditions, including lupus and rheumatoid arthritis. This groundbreaking work aims to reprogram the immune system rather than merely suppressing it.
Transplant Breakthrough
Axiom BioLabs holds the only patent for CAR-T cell therapy in the field of organ transplantation. This revolutionary approach has the potential to eliminate organ rejection and transform transplant medicine worldwide.
Bioengineering
Our interdisciplinary team integrates biology, chemistry, physics, and advanced genomics to engineer CAR-T cells with enhanced specificity and reduced off-target effects, pushing the boundaries of personalized medicine.
Trials Pipeline
Our active clinical trials pipeline spans multiple disease areas. We are committed to rigorous, ethical research protocols and transparent communication of our findings as we advance toward FDA approval.
Collaboration
We welcome collaboration with academic institutions, pharmaceutical companies, and research organizations. From joint research initiatives to licensing opportunities, contact us to explore how we can advance cell therapy together.